{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:16Z","timestamp":1791492676720,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.semarthrit.2025.152911","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:34:54Z","timestamp":1767339294000},"page":"152911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-7351","authenticated-orcid":false,"given":"Jacopo","family":"Ciaffi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9987-7657","authenticated-orcid":false,"given":"Ginevra","family":"Torrigiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-8551","authenticated-orcid":false,"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-3858","authenticated-orcid":false,"given":"Antonella","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-8642","authenticated-orcid":false,"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2025.152911_bib0001","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"issue":"10441","key":"10.1016\/j.semarthrit.2025.152911_bib0003","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152911_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152911_bib0005","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","article-title":"A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development","volume":"7","author":"Li","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0006","series-title":"A comprehensive review of SARS-CoV-2 vaccines","volume":"18","author":"Patel","year":"2022"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152911_bib0007","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"The Lancet Infectious Diseases"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152911_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103340","article-title":"Insights into new-onset autoimmune diseases after COVID-19 vaccination","volume":"22","author":"Guo","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152911_bib0009","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/annrheumdis-2021-220606","article-title":"Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group","volume":"80","author":"Ursini","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152911_bib0010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/annrheumdis-2021-221587","article-title":"Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases","volume":"81","author":"Ursini","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152911_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003022","article-title":"Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group","volume":"9","author":"Ursini","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241261165","article-title":"COVID-19 vaccine-associated vasculitis: a systematic review","volume":"12","author":"Abuhammad","year":"2024","journal-title":"SAGE Open Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152911_bib0013","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/medicina59122127","article-title":"Giant Cell Arteritis after COVID-19 Vaccination with Long-Term Follow-Up: a Case Report and Review of the Literature","volume":"59","author":"Yoshimoto","year":"2023","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0014","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.21608","article-title":"A Case of Giant Cell Arteritis Presenting After COVID-19 Vaccination: is it Just a Coincidence?","author":"Greb","year":"2022","journal-title":"Cureus [Internet]"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdcr.2022.09.026","article-title":"New diagnosis of systemic lupus erythematosus after COVID-19 vaccination: a case report and review of literature","volume":"30","author":"Khanna","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152911_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5152\/eurjrheum.2022.21120","article-title":"Systemic Lupus Erythematosus Following COVID-19 Vaccination","volume":"9","author":"Mohd Salleh","year":"2022","journal-title":"EJR"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152911_bib0017","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.3390\/biomedicines12122800","article-title":"Increased Risk of Myositis-Specific and Myositis-Associated Autoantibodies After COVID-19 Pandemic and Vaccination: a Spanish Multicenter Collaborative Study","volume":"12","author":"Garc\u00eda-Bravo","year":"2024","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152911_bib0018","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12026-023-09368-2","article-title":"COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report","volume":"71","author":"Syrmou","year":"2023","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152911_bib0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-024-03296-8","article-title":"Vaccination and the risk of systemic lupus erythematosus: a meta-analysis of observational studies","volume":"26","author":"Wang","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152911_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102732","article-title":"Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review","volume":"20","author":"Liozon","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152911_bib0021","article-title":"Vasculitis Following Influenza Vaccination: a Review of the Literature","volume":"13","author":"Watanabe","year":"2017","journal-title":"CRR [Internet]"},{"issue":"15_supplement","key":"10.1016\/j.semarthrit.2025.152911_bib0022","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1212\/WNL.96.15_supplement.3046","article-title":"Myopathy after Influenza Vaccination in the United States: a CDC\/FDA Vaccine Adverse Event Reporting System Study, 1990\u20132018 (3046)","volume":"96","author":"Jedidi","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152911_bib0023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1538574418794079","article-title":"A Unique Case Report on Hypersensitivity Vasculitis as an Allergic Reaction to the Herpes Zoster Vaccine","volume":"53","author":"Puram","year":"2019","journal-title":"Vasc Endovascular Surg"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152911_bib0024","first-page":"1116","article-title":"Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases","volume":"28","author":"Zaas","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152827","article-title":"No disproportionate reporting of inflammatory arthritis following COVID-19 vaccination: a pharmacovigilance study using VAERS data","volume":"74","author":"Ciaffi","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"36","key":"10.1016\/j.semarthrit.2025.152911_bib0026","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152911_bib0027","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0028","unstructured":"VAERS - Report an Adverse Event [Internet]. [cited 2025 Feb 2]. Available from: https:\/\/vaers.hhs.gov\/reportevent.html."},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152911_bib0029","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/14740338.2021.1955101","article-title":"Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines","volume":"20","author":"Sessa","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152911_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/picr.PICR_140_18","article-title":"Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006\u20132017","volume":"11","author":"Neha","year":"2020","journal-title":"Perspect Clin Res"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152911_bib0031","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40264-018-0652-4","article-title":"Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: a Disproportionality Analysis within the VAERS Database","volume":"41","author":"Mouchet","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0032","article-title":"Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: a population-based pharmacovigilance analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152911_bib0034","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2105\/AJPH.2021.306241","article-title":"State Strategies for Addressing Barriers During the Early US COVID-19 Vaccination Campaign","volume":"111","author":"Tewarson","year":"2021","journal-title":"Am J Public Health"},{"issue":"44","key":"10.1016\/j.semarthrit.2025.152911_bib0035","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines \u2014 United States, 2021","volume":"70","author":"Mbaeyi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152911_bib0037","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.vaccine.2024.04.028","article-title":"Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children","volume":"42","author":"Kainth","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0038","article-title":"COVID-19 vaccine hesitancy and associated factors among infertile couples undergoing assisted reproductive treatment","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152911_bib0039","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40264-017-0523-4","article-title":"Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems","volume":"40","author":"Kreimeyer","year":"2017","journal-title":"Drug Saf"},{"issue":"15","key":"10.1016\/j.semarthrit.2025.152911_bib0040","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.3390\/ijms23158235","article-title":"Usefulness of Vaccine Adverse Event Reporting System for Machine-Learning Based Vaccine Research: a Case Study for COVID-19 Vaccines","volume":"23","author":"Flora","year":"2022","journal-title":"IJMS"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152911_bib0042","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiology and Drug"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152911_bib0043","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiology and Drug"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152911_bib0044","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: recommendations for Limiting False-Positive Associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152911_bib0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"37","key":"10.1016\/j.semarthrit.2025.152911_bib0046","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1016\/j.vaccine.2020.07.007","article-title":"Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 \u20132019","volume":"38","author":"Moro","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109882","article-title":"Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United States","volume":"259","author":"Kim","year":"2024","journal-title":"Clinical Immunology"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152911_bib0048","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1038\/s41467-024-50656-8","article-title":"Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study","volume":"15","author":"Jung","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102154","article-title":"Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study","volume":"63","author":"Peng","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102898","article-title":"Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review","volume":"132","author":"Rodr\u00edguez","year":"2022","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152911_bib0051","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s10067-022-06078-2","article-title":"Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases","volume":"41","author":"Ursini","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152911_bib0052","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/vaccines9080815","article-title":"Vaccinations and Autoimmune Diseases","volume":"9","author":"Olivieri","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109061","article-title":"Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination","volume":"110","author":"Safary","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152911_bib0054","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152911_bib0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716469","article-title":"NF-\u03baB: at the Borders of Autoimmunity and Inflammation","volume":"12","author":"Barnabei","year":"2021","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152911_bib0057","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","article-title":"Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune\/inflammatory syndrome expand?","volume":"41","author":"Jara","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.06.012","article-title":"Bystander activation and autoimmunity","volume":"103","author":"Pacheco","year":"2019","journal-title":"J Autoimmun"},{"issue":"14","key":"10.1016\/j.semarthrit.2025.152911_bib0059","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood.2021012938","article-title":"Anti\u2013platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152911_bib0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-98313-4","article-title":"Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination","volume":"15","author":"Fraenza","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.756633","article-title":"Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States","volume":"9","author":"Montano","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152911_bib0064","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0065","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.semarthrit.2025.152911_bib0066","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2017.07.005","article-title":"Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting","volume":"123","author":"Mascolo","year":"2017","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152911_bib0067","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jsps.2022.10.001","article-title":"Vaccine adverse event reporting system (VAERS): evaluation of 31 years of reports and pandemics\u2019 impact","volume":"30","author":"Almadani","year":"2022","journal-title":"Saudi Pharmaceutical Journal"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152911_bib0069","article-title":"American College of Rheumatology Guidance for COVID -19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis & Rheumatology [Internet]"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:40:30Z","timestamp":1791492030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225002823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":63,"alternative-id":["S0049017225002823"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152911","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152911"}}